Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KLK7 | P49862 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30832840 | 1.00 | KMT2A (0.65) | KMT2AMEN1PKMMAPTKDM4E | |
| SCHEMBL20773177 | 0.88 | MAPT (0.68) | KMT2AMEN1PKMMAPTKDM4E | |
| SCHEMBL6740302 | 0.86 | MEN1 (0.69) | KMT2AMEN1PKMMAPTKDM4E | |
| SCHEMBL20777415 | 0.85 | KMT2A (0.62) | KMT2AMEN1PKMMAPTKDM4E | |
| SCHEMBL22425071 | 0.84 | KMT2A (0.64) | KMT2AMEN1PKMMAPTKDM4E | |
| SCHEMBL20772671 | 0.83 | MAPT (0.69) | KMT2AMEN1PKMMAPTKDM4E | |
| SCHEMBL13293334 | 0.83 | MAPT (0.78) | KMT2AMEN1PKMMAPTKDM4E | |
| SCHEMBL22424868 | 0.82 | MAPT (0.57) | KMT2AMEN1PKMMAPTKDM4E | |
| SCHEMBL20775957 | 0.80 | KMT2A (0.67) | KMT2AMEN1PKMMAPTKDM4E | |
| SCHEMBL22425304 | 0.78 | KMT2A (0.64) | KMT2AMEN1PKMMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3679027-A1 | DIHYDROBENZIMIDAZOLONES | C4 Therapeutics, Inc. (US) | 2020-07-15 | — | — | EP | claimed |
| CN-111315735-A | Dihydrobenzimidazolones | C4医药公司 | 2020-06-19 | — | — | CN | claimed |
| WO-2019043217-A1 | DIHYDROBENZIMIDAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-07 | — | — | WO | claimed |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| CN-118206529-A | Dihydrobenzimidazolone | C4医药公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| CN-111315735-B | Dihydrobenzimidazolone | C4医药公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220289738-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-20220289738-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-11254672-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254672-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3679027-A1 | DIHYDROBENZIMIDAZOLONES | C4 Therapeutics, Inc. (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200207764-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200207764-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| CN-111315735-A | Dihydrobenzimidazolones | C4医药公司 | 2020-06-19 | — | — | CN | disclosed |
| WO-2019043217-A1 | DIHYDROBENZIMIDAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019043217-A1 | DIHYDROBENZIMIDAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207764-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | KMT2A 1817/4885MEN1 2663/4885PKM 3153/4885 |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | KMT2A 1817/4885MEN1 2663/4885PKM 3153/4885 |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | KMT2A 1817/4885MEN1 2663/4885PKM 3153/4885 |
| US-20220289738-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | KMT2A 1817/4885MEN1 2663/4885PKM 3153/4885 |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | KMT2A 1817/4885MEN1 2663/4885PKM 3153/4885 |
| US-11254672-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | KMT2A 1817/4885MEN1 2663/4885PKM 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.